Education
About Us
Working with TipRanks
Follow Us
Achilles Therapeutics (ACHL)
NASDAQ:ACHL
ACHL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.63 - $1.41
Previous CloseN/A
Volume89.54K
Average Volume (3M)2.02M
Market Cap
$56.31M
Enterprise Value-$41.20M
Total Cash (Recent Filing)-$10.68M
Total Debt (Recent Filing)$121.75K
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 13, 2025EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,087,902
10 Day Avg. Volume2,329,202
30 Day Avg. Volume2,017,397
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.71
Enterprise Value/Ebitda0.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Achilles Therapeutics News
PremiumCompany Announcements
Achilles Therapeutics to Delist from Nasdaq and Deregister with SEC
PremiumCompany Announcements
Achilles Therapeutics Proposes Voluntary Liquidation to Return Capital
PremiumCompany Announcements
Achilles Therapeutics Announces Board Resignations Amid Strategic Realignment
PremiumCompany Announcements
Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.05% Mutual Funds
― Other Institutional Investors
99.95% Public Companies and Individual Investors
ACHL FAQ
What was Achilles Therapeutics’s price range in the past 12 months?
Achilles Therapeutics lowest stock price was $0.63 and its highest was $1.41 in the past 12 months.
What is Achilles Therapeutics’s market cap?
Achilles Therapeutics’s market cap is $56.31M.
When is Achilles Therapeutics’s upcoming earnings report date?
Achilles Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 68 days.
How were Achilles Therapeutics’s earnings last quarter?
Currently, no data Available
Is Achilles Therapeutics overvalued?
According to Wall Street analysts Achilles Therapeutics’s price is currently Overvalued.
Does Achilles Therapeutics pay dividends?
Achilles Therapeutics does not currently pay dividends.
What is Achilles Therapeutics’s EPS estimate?
Achilles Therapeutics’s EPS estimate is -0.36.
How many shares outstanding does Achilles Therapeutics have?
Achilles Therapeutics has 41,087,902 shares outstanding.
What happened to Achilles Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Achilles Therapeutics?
Currently, no hedge funds are holding shares in ACHL
---
Achilles Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.92%
12-Months-Change
Fundamentals
Return on Equity
-52.41%
Trailing 12-Months
Asset Growth
-30.03%
Trailing 12-Months
Company Description
Achilles Therapeutics
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
---
ACHL Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Immatics
―
Best Analysts Covering ACHL
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-41.58%
reiterated a buy rating 11 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -41.58% per trade.
---